UBS AM’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-44,557
| Closed | -$867K | – | 2844 |
|
|
2018
Q1 | $867K | Buy |
44,557
+10,891
| +32% | +$214K | ﹤0.01% | 1837 |
|
|
2017
Q4 | $561K | Hold |
33,666
| – | – | ﹤0.01% | 1932 |
|
|
2017
Q3 | $683K | Buy |
33,666
+507
| +2% | +$9.69K | ﹤0.01% | 1842 |
|
|
2017
Q2 | $534K | Sell |
33,159
-5,349
| -14% | -$79K | ﹤0.01% | 1861 |
|
|
2017
Q1 | $487K | Buy |
38,508
+23,092
| +150% | +$279K | ﹤0.01% | 1878 |
|
|
2016
Q4 | $204K | Sell |
15,416
-1,015,163
| -99% | -$17.4M | ﹤0.01% | 2121 |
|
|
2016
Q3 | $24.4M | Sell |
1,030,579
-390,051
| -27% | -$10.5M | 0.03% | 607 |
|
|
2016
Q2 | $40.9M | Sell |
1,420,630
-66,250
| -4% | -$2.16M | 0.05% | 413 |
|
|
2016
Q1 | $47.6M | Sell |
1,486,880
-341,335
| -19% | -$12M | 0.06% | 369 |
|
|
2015
Q4 | $78.2M | Buy |
1,828,215
+57,206
| +3% | +$2.29M | 0.09% | 248 |
|
|
2015
Q3 | $62.4M | Buy |
1,771,009
+8,548
| +0.5% | +$385K | 0.07% | 306 |
|
|
2015
Q2 | $80.9M | Sell |
1,762,461
-259,470
| -13% | -$12.3M | 0.08% | 276 |
|
|
2015
Q1 | $94.8M | Sell |
2,021,931
-80,548
| -4% | -$3.21M | 0.09% | 255 |
|
|
2014
Q4 | $66.6M | Sell |
2,102,479
-129,935
| -6% | -$3.8M | 0.06% | 328 |
|
|
2014
Q3 | $52.9M | Buy |
2,232,414
+39,905
| +2% | +$1.02M | 0.05% | 377 |
|
|
2014
Q2 | $65.8M | Sell |
2,192,509
-104,109
| -5% | -$2.81M | 0.07% | 314 |
|
|
2014
Q1 | $60.7M | Buy |
2,296,618
+8,780
| +0.4% | +$219K | 0.06% | 319 |
|
|
2013
Q4 | $57.5M | Buy |
2,287,838
+180,514
| +9% | +$4.03M | 0.07% | 325 |
|
|
2013
Q3 | $43.2M | Sell |
2,107,324
-51,735
| -2% | -$1.07M | 0.05% | 360 |
|
|
2013
Q2 | $43.1M | Buy |
+2,159,059
| New | +$38.3M | 0.06% | 351 |
|
UBS AM's IPXL Position: Q2 2018 in Review
UBS AM sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 44,557 shares — an estimated $867K sold.
UBS AM first reported a position in IPXL in Q2 2013 and held it in 20 quarters. The position peaked at $94.8M in Q1 2015. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- UBS AM reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- UBS AM sold 44,557 Impax Laboratories, Inc. shares in Q2 2018, an estimated $867K.
- UBS AM first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 20 quarters.
- UBS AM's Impax Laboratories, Inc. position peaked at $94.8M in Q1 2015.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on UBS AM's 13F filing for Q2 2018, filed 14 Aug 2018.